Poniard Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics. Its lead platform product candidate includes Picoplatin, a platinum-based cancer therapy to treat multiple cancer indications, including small cell lung, colorectal, prostate, and ovarian cancers. The company has conducted a pivotal Phase III SPEAR trial of Picoplatin in the second-line treatment of patients with small cell lung cancer; Phase II trials evaluating picoplatin as a first-line treatment of metastatic colorectal cancer and castration-resistant prostate cancer; and a Phase I study evaluating an oral formulation of picoplatin in solid tumors. The company was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in September 2006. Poniard Pharmaceuticals, Inc. was founded in 1984 and is based in Seattle, Washington.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone206-286-2501
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
OptionableNot Optionable
Poniard Pharmaceuticals (OTCMKTS:PARD) Frequently Asked Questions
What is Poniard Pharmaceuticals' stock symbol?
Poniard Pharmaceuticals trades on the OTCMKTS under the ticker symbol "PARD."
Has Poniard Pharmaceuticals been receiving favorable news coverage?
Press coverage about PARD stock has been trending very positive recently, according to InfoTrie Sentiment. The research firm scores the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Poniard Pharmaceuticals earned a daily sentiment score of 3.3 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next few days.
Who are some of Poniard Pharmaceuticals' key competitors?
Some companies that are related to Poniard Pharmaceuticals include Targeted Medical Pharma (TRGM), Immune Pharmaceuticals (IMNP), HST Global (HSTC), Aeolus Pharmaceuticals (AOLS), Spotlight Innovation (STLT), Tetralogic Pharmaceuticals (TLOG), Orexigen Therapeutics (OREXQ), Epirus Biopharmaceuticals (EPRSQ), Inspyr Therapeutics (NSPX), Tianyin Pharmaceutical (TPIY), Advanced Accelerator Application (AAAP), American Oriental Bioengineering (AOBI), Aralez Pharmaceuticals (ARLZ), ARMO Biosciences (ARMO) and Bohai Pharmaceuticals Group (BOPH).
Who are Poniard Pharmaceuticals' key executives?
Poniard Pharmaceuticals' management team includes the folowing people:
- Dr. Paul G. Abrams, Exec. Officer
How do I buy shares of Poniard Pharmaceuticals?
Shares of PARD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Poniard Pharmaceuticals' stock price today?
One share of PARD stock can currently be purchased for approximately $0.0580.
How big of a company is Poniard Pharmaceuticals?
Poniard Pharmaceuticals has a market capitalization of $87,000.00.
What is Poniard Pharmaceuticals' official website?
How can I contact Poniard Pharmaceuticals?
Poniard Pharmaceuticals' mailing address is 750 BATTERY STREET SUITE 330, SAN FRANCISCO CA, 98119-4114. The biopharmaceutical company can be reached via phone at 206-286-2501 or via email at [email protected]
MarketBeat Community Rating for Poniard Pharmaceuticals (OTCMKTS PARD)
MarketBeat's community ratings are surveys of what our community members think about Poniard Pharmaceuticals and other stocks. Vote "Outperform" if you believe PARD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PARD will underperform the S&P 500 over the long term. You may vote once every thirty days.
